Stage IV colon cancer patients without DENND2D expression benefit more from neoadjuvant chemotherapy
Work
Year: 2022
Type: article
Abstract: According to the EPOC study, chemotherapy could improve 5-year disease-free survival of stage IV colon cancer patients by 8.1%. However, more molecular biomarkers are required to identify patients wh... more
Source: Cell Death and Disease
Institutions State Key Laboratory of Oncology in South China, Key Laboratory of Guangdong Province, Sun Yat-sen University, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University +5 more
Cites: 68
Cited by: 3
Related to: 10
FWCI: 0.493
Citation percentile (by year/subfield): 62.72
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: gold
APC paid (est): $3,422